Unichem Laboratories Limited has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled for Friday, May 22, 2026. The intimation was filed on May 6, 2026, in compliance with Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The Board meeting has been convened to consider and approve the financial results for the quarter and full year ended March 31, 2026. The agenda covers both standalone and consolidated financial statements, as detailed below:

Regulatory Compliance

The intimation was submitted to both BSE Limited and the National Stock Exchange of India Limited, fulfilling the company's disclosure obligations under applicable SEBI regulations. The filing was signed by Pradeep Bhandari, Head – Legal & Company Secretary of Unichem Laboratories Limited.

Unichem Laboratories has informed stock exchanges about a voluntary product recall by its US subsidiary under regulatory disclosure requirements. The pharmaceutical company's wholly-owned subsidiary, Unichem Pharmaceuticals (USA), Inc., has initiated a recall of specific products distributed in the United States market.

Product Recall Details

The recall involves Buspirone Hydrochloride Tablets that failed to meet quality specifications during routine stability testing. The company discovered out-of-specification assay results at the 12-month long-term stability time point, prompting the voluntary recall action.

Safety and Quality Assurance

Unichem Laboratories has confirmed that no adverse events related to this recall have been reported to date. The company emphasized its commitment to patient safety, stating that it places the highest priority on ensuring patient safety and maintaining product quality throughout every stage of its manufacturing and supply chain processes.

Regulatory Compliance

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was addressed to both the National Stock Exchange of India Limited and BSE Limited, ensuring compliance with mandatory disclosure requirements for listed companies.

The voluntary nature of the recall demonstrates the company's proactive approach to quality control and regulatory compliance in international markets. Such recalls, while impacting operations, reflect pharmaceutical companies' adherence to stringent quality standards and patient safety protocols.